A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain



Status:Active, not recruiting
Conditions:Breast Cancer, Lung Cancer, Lung Cancer, Skin Cancer, Cancer, Brain Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:12/19/2018
Start Date:April 20, 2015
End Date:November 8, 2019

Use our guide to learn which trials are right for you!

A Phase 2 Study of Abemaciclib in Patients With Brain Metastases Secondary to Hormone Receptor Positive Breast Cancer, Non-small Cell Lung Cancer, or Melanoma

The main purpose of this study is to evaluate the safety and effectiveness of the study drug
known as abemaciclib in participants with hormone receptor positive breast cancer, non-small
cell lung cancer (NSCLC), or melanoma that has spread to the brain.


Inclusion Criteria:

- Have brain metastases secondary to hormone receptor positive breast cancer, NSCLC, or
melanoma.

- Have either human epidermal growth factor receptor 2 positive (HER2+) (Study Part A)
or HER2- (Study Part B) breast cancer.

- Participants in Study Part C must have HR+ breast cancer, NSCLC, or melanoma with
brain lesions clinically indicated for surgical resection as well as consent to
provide tissue for drug concentration determination after 5 to 14 days of study drug
dosing.

- Participants in Part D must have NSCLC of any subtype.

- Participants in Part E must have melanoma of any subtype.

- Participants in Part F must have HR+ breast cancer, NSCLC, or melanoma with
leptomeningeal metastases.

- For Parts A, B, D, and E: Must have at least 1 measurable brain lesion ≥10 millimeters
(mm) in the longest diameter (LD).

- For Part C (surgical): Have metastatic brain lesion(s) for which surgical resection is
clinically indicated.

- Have completed local therapy (surgical resection, WBRT, or SRS) ≥14 days prior to
initiating abemaciclib and recovered from all acute effects.

- If receiving concomitant corticosteroids, must be on a stable or decreasing dose for
at least 7 days prior to the baseline Gd-MRI.

- Have a Karnofsky performance status of ≥70.

- Have a life expectancy ≥12 weeks.

- For HR+ breast cancer participants in part A, B, C, and F: If currently receiving
endocrine therapy, a participant may continue to receive the same endocrine therapy
provided that extracranial disease is stable for at least 3 months and central nervous
system (CNS) disease progression has occurred while on this endocrine therapy. If
these conditions are not met, participants must discontinue endocrine therapy prior to
initiation of abemaciclib.

- For HER2+ breast cancer participants in parts A, C, and F: participants may receive
concurrent treatment (ongoing or initiated simultaneously with abemaciclib) with IV
trastuzumab.

- For NSCLC participants in parts C, D, and F: if currently receiving gemcitabine or
pemetrexed (single-agent or in combination with another therapy), a participant may
continue to receive 1 of these 2 therapies provided that extracranial disease is
stable for at least 6 weeks and CNS disease progression has occurred while on this
therapy.

- Have adequate organ function.

Exclusion Criteria:

- Require immediate local therapy, including but not limited to WBRT, SRS, or surgical
resection, for treatment of brain metastases.

- Are taking concurrent enzyme-inducing antiepileptic drugs (EIAED).

- Have evidence of significant (ie, symptomatic) intracranial hemorrhage.

- For Parts A, B, C, D, E: Have evidence of leptomeningeal metastases. Note: discrete
dural metastases are permitted.

- Have experienced >2 seizures within 4 weeks prior to study entry.

- For Parts A, B, D, E, and F: Have previously received treatment with any cyclin
dependent kinase 6 (CDK6) inhibitor. For Part C participants may have received prior
palbociclib or ribociclib, but not abemaciclib treatment.

- Have known contraindication to Gd-MRI.

- Have a preexisting chronic condition resulting in persistent diarrhea.
We found this trial at
20
sites
3840 Broadway
Fort Myers, Florida 33901
(239) 275-6400
Principal Investigator: Lowell Hart
Phone: 239-275-6400
?
mi
from
Fort Myers, FL
Click here to add this to my saved trials
Chapel Hill, North Carolina 27599
(919) 962-2211
Principal Investigator: Carey Anders
Phone: 919-966-4431
University of North Carolina at Chapel Hill Carolina’s vibrant people and programs attest to the...
?
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
2200 Santa Monica Blvd
Santa Monica, California 90404
(310) 582-7438
Principal Investigator: Santosh Kesari
Phone: 310-829-8265
?
mi
from
Santa Monica, CA
Click here to add this to my saved trials
500 S State St
Ann Arbor, Michigan 48109
(734) 764-1817
Principal Investigator: Aki Morikawa
Phone: 734-764-1817
University of Michigan The University of Michigan was founded in 1817 as one of the...
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Aurora, Colorado 80045
Principal Investigator: Peter Kabos
Phone: 720-848-1030
?
mi
from
Aurora, CO
Click here to add this to my saved trials
450 Brookline Ave
Boston, Massachusetts 2215
617-632-3000
Principal Investigator: Sara Tolaney
Phone: 617-632-3800
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
?
mi
from
Boston, MA
Click here to add this to my saved trials
1500 East Duarte Road
Duarte, California 91010
626-256-HOPE (4673)
Principal Investigator: Jana Portnow
Phone: 626-256-4673
City of Hope National Medical Center City of Hope is dedicated to making a difference...
?
mi
from
Duarte, CA
Click here to add this to my saved trials
Honolulu, Hawaii 96817
Principal Investigator: Jennifer Carney
Phone: 808-432-8587
?
mi
from
Honolulu, HI
Click here to add this to my saved trials
1515 Holcombe Blvd
Houston, Texas 77030
 713-792-2121
Principal Investigator: Siqing Fu
Phone: 713-792-9669
University of Texas M.D. Anderson Cancer Center The mission of The University of Texas MD...
?
mi
from
Houston, TX
Click here to add this to my saved trials
9500 Gilman Dr
La Jolla, California 92093
(858) 534-2230
Principal Investigator: David Piccioni
The University of California, San Diego UC San Diego is an academic powerhouse and economic...
?
mi
from
La Jolla, CA
Click here to add this to my saved trials
529 S Jackson St
Louisville, Kentucky 40202
(502) 562-4369
Principal Investigator: Goetz Kloecker
Phone: 502-562-4246
James Graham Brown Cancer Center No one should feel compelled to leave Kentucky to seek...
?
mi
from
Louisville, KY
Click here to add this to my saved trials
Nashville, Tennessee 37203
Principal Investigator: Sarah Cannon Research Inst.
Phone: 615-329-7615
?
mi
from
Nashville, TN
Click here to add this to my saved trials
250 25th Ave N, Ste 100
Nashville, Tennessee 37023
615-320-5090
Principal Investigator: Denise Yardley
Phone: 615-340-2827
Tennessee Oncology, PLLC Since 1976 Tennessee Oncology has been providing quality cancer care. In 2013,...
?
mi
from
Nashville, TN
Click here to add this to my saved trials
?
mi
from
Nedlands,
Click here to add this to my saved trials
1275 York Ave
New York, New York 10021
(212) 639-2000
Principal Investigator: Mariza Daras
Phone: 212-639-3709
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
?
mi
from
New York, NY
Click here to add this to my saved trials
Portland, Oregon 97213
Principal Investigator: Alison Conlin
Phone: 506-216-8636
?
mi
from
Portland, OR
Click here to add this to my saved trials
Saint Louis, Missouri 63110
Principal Investigator: Michael Naughton
Phone: 314-996-8270
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
San Francisco, California 94143
Principal Investigator: Michelle Melisko
Phone: 415-885-3732
?
mi
from
San Francisco, CA
Click here to add this to my saved trials
Tampa, Florida 33612
Principal Investigator: Solmaz Sahebjam
Phone: 813-745-3871
?
mi
from
Tampa, FL
Click here to add this to my saved trials
3800 Reservoir Rd NW
Washington, District of Columbia 20007
(202) 687-7695
Principal Investigator: Deepa Subramaniam
Phone: 202-444-2198
Georgetown University Medical Center Georgetown University Medical Center is committed to excellence in research, education...
?
mi
from
Washington,
Click here to add this to my saved trials